Rodney, Simon
Banerji, Udai http://orcid.org/0000-0003-1503-3123
Article History
First Online: 21 December 2023
Competing interests
: The Drug Development Unit is a joint department of the Institute of Cancer Research and The Royal Marsden NHS Foundation Trust. The Institute of Cancer Research has research and commercial interests in licensed drugs such as abiraterone and capivasertib, and classes of drugs such as inhibitors of HSP90, HDAC, PI3K, alpha folate targeted thymidylate synthase, CHK1, MPS-1, GSPT-1 degraders and HSF-1 pathway. The unit receives funding from the Cancer Research UK Convergence Science Centre and the Experimental Cancer Centre and Biomedical Research Centre initiatives. The opinions expressed are personal. U.B. has received honoria for participation in advisory boards from Ellipsis Pharma, PharmEnable, Carrick Therapeutics and Pegasy, has received funding for preclinical research from Avacta and Verastem Oncology and clinical trial funding from Verastem Oncology. S.R. declares no competing interests.